Literature DB >> 11273224

An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy.

J B Angel1, Y Khaliq, M L Monpetit, D W Cameron, K Gallicano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11273224     DOI： 10.1097/00002030-200102160-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  10 in total

1.  Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.

Authors:  Déborah Hirt; Jean-Marc Treluyer; Vincent Jullien; Ghislaine Firtion; Hélène Chappuy; Elisabeth Rey; Gérard Pons; Laurent Mandelbrot; Saïk Urien
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina.

Authors:  Huixia Zhang; Xiaohui Wu; Francisco Chung; Suresh Babu Naraharisetti; Dale Whittington; Ahmad Mirfazaelian; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-03-17       Impact factor: 4.030

Review 6.  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Authors:  Matthieu Roustit; Malik Jlaiel; Pascale Leclercq; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

7.  Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Authors:  Y J Bryson; M Mirochnick; A Stek; L M Mofenson; J Connor; E Capparelli; D H Watts; S Huang; M D Hughes; K Kaiser; L Purdue; Y Asfaw; M Keller; E Smith
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr

8.  Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.

Authors:  Huixia Zhang; Xiaohui Wu; Suresh Babu Naraharisetti; Francisco Chung; Dale Whittington; Ahmad Mirfazaelian; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

9.  Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Authors:  Rosa F Yeh; Naser L Rezk; Angela D M Kashuba; Julie B Dumond; Hiba L Tappouni; Hsiao-Chuan Tien; Ya-Chi Chen; Manoli Vourvahis; Amanda L Horton; Susan A Fiscus; Kristine B Patterson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

10.  Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course.

Authors:  Huixia Zhang; Xiaohui Wu; Honggang Wang; Andrei M Mikheev; Qingcheng Mao; Jashvant D Unadkat
Journal:  Mol Pharmacol       Date:  2008-05-28       Impact factor: 4.054
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.